Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Regeneron Pharmaceuticals
REGNHealthcareGenerated Jul 5, 2026, 08:09 PM UTC
REGN (Regeneron Pharmaceuticals) analytical snapshot. Return on equity 17.44%, ROA 10.47%, ROIC 16.42%. Net income down ▼ +8.9% YoY. Debt/equity 0.06, current ratio 3.57, net debt -$976.4M. Market cap $61.47B at $654.27 per share. Trailing P/E 18.82, P/S 14.98, P/B 1.96. EV/Operating income ≈ 14.95 (EV $60.50B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score -4 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$61.47B
93.96M shares
Price
$654.27
NMS
P/E (ttm)
18.82
Revenue (FY)
—
Net margin
—
Free cash flow
$3.88B
Risk level
Low
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 5Stable
80% conf
Return on equity 17.44%, ROA 10.47%, ROIC 16.42%. Net income down ▼ +8.9% YoY. Debt/equity 0.06, current ratio 3.57, net debt -$976.4M.
- Return on equity 17.44%, ROA 10.47%, ROIC 16.42%.
- Net income down ▼ +8.9% YoY.
- Debt/equity 0.06, current ratio 3.57, net debt -$976.4M.
Revenue (FY)
—
Net margin
—
ROE
17.44%
ROA 10.47%
ROIC
16.42%
EPS (diluted)
$34.77
FY2025
Free cash flow
$3.88B
Debt / equity
0.06
Cash $2.96B
Current ratio
3.57
Equity $31.42B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $2.82B | — | 0.00 | 29.22 | 11.99 | $419.4M | 17.21 |
| 2017 | $4.10B | +45.5% | 0.00 | 30.51 | 15.50 | $652.8M | 24.94 |
| 2018 | — | — | — | — | — | $974.0M | 24.50 |
| 2019 | — | — | — | — | — | $1.03B | 26.94 |
| 2020 | — | — | — | — | — | $1.81B | 39.78 |
| 2021 | — | — | — | — | — | $2.00B | 24.16 |
| 2022 | — | — | — | — | — | $2.00B | 31.68 |
| 2023 | — | — | — | — | — | $6.53B | 73.24 |
| 2024 | — | — | — | — | — | $4.42B | 23.11 |
| 2025 | — | — | — | — | — | $3.88B | 17.44 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2017 | $1.32B | +9.8% | — | 18.87% |
| Jun 30, 2017 | $2.79B | +15.6% | +111.5% | 22.83% |
| Jun 30, 2017 | $1.47B | -39.1% | -47.3% | 43.31% |
| Sep 30, 2017 | $4.29B | +18.1% | +191.8% | 23.89% |
| Sep 30, 2017 | $1.50B | -58.7% | -65.0% | 68.30% |
| Mar 31, 2018 | $1.51B | +14.6% | +0.7% | 31.62% |
Revenue (annual, SEC 10-K)
2016: 2,820
2017: 4,104
2018: 0
2019: 0
2020: 0
2021: 0
2022: 0
2023: 0
2024: 0
2025: 0
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 419
2017: 653
2018: 974
2019: 1,035
2020: 1,812
2021: 2,000
2022: 2,004
2023: 6,529
2024: 4,425
2025: 3,875
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Feb 4, 2026. Latest quarterly report (10-Q) filed Apr 29, 2026. 14 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 4, 2026.
- Latest quarterly report (10-Q) filed Apr 29, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Regeneron Pharmaceuticals; broad institutional reporting.
- Recent filers include BAKER BROS ADVISORS LLC, BAKER BROS ADVISORS LLC, CANYON CAPITAL ADVISORS LLC.
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 4, 2026
Annual report
Latest 10-Q
Apr 29, 2026
8-K (recent)
14
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| BAKER BROS ADVISORS LLC | 13F-HR | Sep 19, 2003 |
| BAKER BROS ADVISORS LLC | 13F-HR | Sep 19, 2003 |
| CANYON CAPITAL ADVISORS LLC | 13F-HR | May 15, 2003 |
| CANYON CAPITAL ADVISORS LLC | 13F-HR | Aug 15, 2002 |
| Invus Public Equities Advisors, LLC | 13F-HR | Nov 13, 2007 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 17, 2026 | 8-K | FORM 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Apr 8, 2026 | 8-K | FORM 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | FORM 8-K |
| Oct 28, 2025 | 8-K | 8-K |
| Oct 6, 2025 | 8-K | FORM 8-K |
| Aug 1, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -46Deteriorating
70% conf
3 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Deferred revenue growing — future revenue visibility: Deferred revenue grew +50.9% to $231.7M, providing forward revenue visibility. This is a positive leading indicator for subscription or contract-based businesses.
- R&D intensity declining: R&D as % of revenue fell from 127.4% to 108.2%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$4.10B
+45.5% YoY
Operating income
$4.05B
-14.6% YoY
Net income
$3.95B
-8.9% YoY
Operating cash flow
$4.59B
-8.4% YoY
Capex
$718.6M
+21.8% YoY
Total assets
$37.76B
+14.1% YoY
Total liabilities
$8.41B
+18.3% YoY
Long-term debt
$1.98B
+0.1% YoY
Filing quality score
72/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $2.82B | $4.10B | $1.28B | +45.5% |
| Operating income | $4.74B | $4.05B | $-691.8M | -14.6% |
| Net income | $4.34B | $3.95B | $-384.8M | -8.9% |
| Operating cash flow | $5.01B | $4.59B | $-420.9M | -8.4% |
| Capex | $590.1M | $718.6M | $128.5M | +21.8% |
| Total assets | $33.08B | $37.76B | $4.68B | +14.1% |
| Total liabilities | $7.11B | $8.41B | $1.30B | +18.3% |
| Long-term debt | $1.98B | $1.98B | $1.5M | +0.1% |
| Cash & equivalents | $3.11B | $2.73B | $-375.9M | -12.1% |
| Stockholders equity | $18.77B | $22.66B | $3.90B | +20.8% |
| Inventory | $2.58B | $3.09B | $506.8M | +19.6% |
| Accounts receivable | $5.67B | $6.21B | $544.6M | +9.6% |
| R&D expense | $3.59B | $4.44B | $846.5M | +23.6% |
| SG&A expense | $2.12B | $2.63B | $515.4M | +24.4% |
| Interest expense | $56.9M | $57.3M | $400000 | +0.7% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | FinanceLeaseLiabilityCurrent |
| Removed | AccountsPayableAndAccruedLiabilitiesCurrent, AmortizationOfIntangibleAssets, BusinessCombinationContingentConsiderationLiability, CommonStockDividendsPerShareCashPaid, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 1 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 52 | 8 | Ongoing |
| Restructuring | medium | 31 | 9 | Ongoing |
| Off-balance sheet arrangements | medium | 60 | 1 | Ongoing |
| Related party transactions | low | 1 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 1
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $61.47B at $654.27 per share.
- ProPrice & TechnicalsPrice $654.27 — downtrend (below 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Low.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -4
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Regeneron Pharmaceuticals is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewMarket cap $61.47B at $654.27 per share..
Risk
Low
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow REGN stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| CVS Health Corp. CVS | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Regeneron Pharmaceuticals REGN● you | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Danaher Corp. DHR | — | Neutral |
| Intuitive Surgical Inc. ISRG | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Colgate-Palmolive CL | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Kroger Co. KR | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |
| Illumina Inc. ILMN | — | Neutral |
| HCA Healthcare HCA | — | Neutral |